INMB INMUNE BIO INC Product Launches 8-K Filing 2024 - Clinical Trial Update INmune Bio Inc. announced progress in its INKmune therapy for prostate cancer, sharing initial results from the Phase I/II trial.Get access to all SEC 8-K filings of the INMUNE BIO INC